Initially, the new facility will manufacture Avicel colloidal MCC which is used as key ingredient in pharmaceutical and food and beverages industries.
The company said the facility’s design will allow for future volume expansion to manufacture different product for both the pharmaceutical and food markets.
The new facility, which will increase FMC’s food grade MCC capacity by 35%, is expected to commence its operations in the fourth quarter 2014.
FMC specialty chemicals group president Michael Wilson said demand for MCC continues to grow rapidly in Asia.
"This addition of significant new capacity to our MCC network will be needed to supply high-quality products and service to our Asian customers, while at the same time providing us with greater flexibility to support global growth with our existing capacity in North America and Europe," Wilson added.